Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500642PMID: 29999702
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1000120-98-8
Drug Levels and Effects
Summary of Use during Lactation
Mipomersen marketing has been discontinued in the United States. No relevant published information exists with the use of mipomersen during breastfeeding. Because of a concern with disruption of infant lipid metabolism, mipomersen should not be used during breastfeeding.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Mipomersen
CAS Registry Number
1000120-98-8
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.[Clin Pharmacokinet. 2009]Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.Yu RZ, Geary RS, Flaim JD, Riley GC, Tribble DL, vanVliet AA, Wedel MK. Clin Pharmacokinet. 2009; 48(1):39-50.
- Review Mipomersen sodium: first global approval.[Drugs. 2013]Review Mipomersen sodium: first global approval.Hair P, Cameron F, McKeage K. Drugs. 2013 Apr; 73(5):487-93.
- Review Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.[Vasc Health Risk Manag. 2012]Review Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.Bell DA, Hooper AJ, Watts GF, Burnett JR. Vasc Health Risk Manag. 2012; 8:651-9. Epub 2012 Nov 28.
- Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.[J Am Coll Cardiol. 2013]Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. J Am Coll Cardiol. 2013 Dec 10; 62(23):2178-84. Epub 2013 Sep 4.
- Review Mipomersen, an antisense apolipoprotein B synthesis inhibitor.[Expert Opin Investig Drugs. 2011]Review Mipomersen, an antisense apolipoprotein B synthesis inhibitor.Bell DA, Hooper AJ, Burnett JR. Expert Opin Investig Drugs. 2011 Feb; 20(2):265-72. Epub 2011 Jan 6.
- Mipomersen - Drugs and Lactation Database (LactMed®)Mipomersen - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...